^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ATM expression

i
Other names: ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase
Entrez ID:
Related biomarkers:
13d
ATM-deficient murine thymic T-cell lymphoblastic lymphomas are PTEN-deficient and require AKT signaling for survival. (PubMed, PLoS One)
In addition, all T-LBLs demonstrate constitutive expression of pAKT, indicating the presence of activated AKT signaling, and are sensitive to treatment with the pan-AKT inhibitor MK-2206, suggesting that these lymphomas are dependent on pAKT signaling for their survival. Lastly, ATM-deficiency itself does not cause loss of PTEN or dysregulated AKT signaling, as ATM-deficient non-malignant thymocytes express wild-type levels of PTEN and lack detectable pAKT. This study demonstrates for the first time that the majority of ATM-deficient thymic T-LBLs lose PTEN expression and all depend on AKT signaling for survival, suggesting their potential use as an animal model for PI3K/AKT/MTOR pathway dysfunction in human T-ALL.
Preclinical • Journal
|
PTEN (Phosphatase and tensin homolog) • ATM (ATM serine/threonine kinase)
|
PTEN expression • ATM expression • PTEN negative
|
MK-2206
2ms
Tissue microarray analyses of the essential DNA repair factors ATM, DNA-PKcs and Ku80 in head and neck squamous cell carcinoma. (PubMed, Radiat Oncol)
Our data suggest that HPV-negative HNSCC with particularly low Ku80 expression represent a highly radiosensitive subpopulation. Confirmation in independent cohorts is required.
Journal
|
ATM (ATM serine/threonine kinase)
|
ATM expression
2ms
Association of ATM and ARID1A in gastric carcinoma. (PubMed, Pathol Res Pract)
ATMlow in GCs shows a characteristic clinicopathological feature that correlates strongly with ARID1Alow. ATM mutation was also associated with ARID1A mutations, highlighting the interactions between ATM and ARID1A in GC and suggesting a potential therapeutic target.
Journal • MSi-H Biomarker
|
MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
|
MSI-H/dMMR • ARID1A mutation • ATM underexpression • ATM expression
7ms
GZ17-6.02 kills PDX isolates of uveal melanoma. (PubMed, Oncotarget)
GZ17-6.02 interacted with doxorubicin or ERBB family inhibitors to significantly enhance tumor cell killing which was associated with greater levels of autophagosome formation and autophagic flux...The components of GZ17-6.02 were detected in tumors using a syngeneic tumor model. Our data support future testing GZ17-6.02 in uveal melanoma as a single agent, in combination with ERBB family inhibitors, in combination with cytotoxic drugs, or with an anti-PD1 immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BAP1 (BRCA1 Associated Protein 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FADD (Fas associated via death domain) • FAS (Fas cell surface death receptor) • ATG5 (Autophagy Related 5) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • BECN1 (Beclin 1)
|
PD-L1 expression • ATM overexpression • ATM expression • FADD overexpression
|
Gilotrif (afatinib) • Nerlynx (neratinib) • doxorubicin hydrochloride • GZ17-6.02
8ms
Absence of ATM leads to altered NK cell function in mice. (PubMed, Clin Immunol)
Results also suggest that expansion of exhausted NKG2D+ NK cells in Atm-/- mice is driven by low-level expression of stress-inducible NKG2D ligands, whereas development of thymoma expressing the high-affinity MULT1 ligand is associated with NKG2D down-regulation on NK cells. These results expand our understanding of immunodeficiency in A-T and encourage exploring NK cell biology in A-T patients in the attempt to identify cancer predictive biomarkers and novel therapeutic targets.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NKG2D (killer cell lectin like receptor K1)
|
ATM mutation • ATM expression
8ms
Irradiated Tumour Cell-Derived Microparticles Upregulate MHC-I Expression in Cancer Cells via DNA Double-Strand Break Repair Pathway. (PubMed, Cancer Lett)
Furthermore, phosphorylation of STAT1/3 following the activation of ATM/ATR/CHK1 is indispensable for the DSB-dependent upregulation of MHC-I. Therefore, our findings reveal the role of RT-MP-induced DSBs and the subsequent DNA repair signalling pathway in MHC-I expression and provide mechanistic insights into the regulation of MHC-I expression after DSBs.
Journal • Tumor cell
|
CHEK1 (Checkpoint kinase 1)
|
ATM expression
8ms
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. (PubMed, JCO Precis Oncol)
The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
P2 data • Journal
|
ATM (ATM serine/threonine kinase)
|
ATM expression
|
gemcitabine • berzosertib (M6620)
8ms
Immunohistochemical Findings and Clinicopathological Features of Breast Cancers with Pathogenic Germline Mutations in Non-BRCA Genes. (PubMed, Hum Pathol)
With PTEN and CHEK2 pathogenic mutations, abnormal IHC patterns are seen in early atypical proliferative lesions. IHC may be applied to identify CHEK2 &PTEN mutated BCs and precursor lesions.
Journal • BRCA Biomarker
|
PTEN (Phosphatase and tensin homolog) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
|
ATM mutation • PTEN deletion • PTEN mutation • PALB2 mutation • CHEK2 mutation • ATM expression
8ms
Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells. (PubMed, Int J Hyperthermia)
Protein expression levels of DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways significantly decreased in RT + MW-HT groups. MW-HT + RT treatment significantly inhibited DNA damage repair by downregulating DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways, leading to increased ROS levels, aggravate DNA damage, apoptosis, and necrosis in PC3 cells, a well-established model of CRPC.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression • ATM expression
9ms
Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population. (PubMed, Cancers (Basel))
In total, 76% (16/21) of patients with iPGVs co-expressed somatic alterations, with 56% (9/16) demonstrating alterations in targetable genes. Overall, our real-world findings offer a point prevalence of iPGVs in patients with NSCLC of diverse populations, such as patients who report Hispanic/Latinx ethnicity.
Journal • BRCA Biomarker • Circulating tumor DNA
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
|
ATM expression
|
Guardant360® CDx
10ms
Toward the complete understanding of the pathogenic mechanism of clioquinol-induced subacute myelo-optic neuropathy (SMON) (PubMed, Nihon Yakurigaku Zasshi)
We also demonstrated that clioquinol induced zinc influx and oxidation of the copper chaperone ATOX1, leading to the impairment of the functional maturation of a copper-dependent enzyme dopamine-β-hydroxylase and the inhibition of noradrenaline biosynthesis. Thus, clioquinol-induced neurotoxicity in SMON seems to be mediated by multiple pathways.
Journal
|
GATA2 (GATA Binding Protein 2) • GATA3 (GATA binding protein 3) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
|
ATM expression
10ms
Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC) (AACR 2024)
Responses to ceralasertib monotherapy were limited in ATM-altered tumors, despite reaching target plasma levels. Alternative pt selection and combination treatment strategies are being explored.
Clinical • Metastases
|
ATM expression
|
FoundationOne® CDx
|
ceralasertib (AZD6738)
10ms
A-T neurodegeneration and DNA damage-induced transcriptional stress. (PubMed, DNA Repair (Amst))
In addition, innate immunity signaling pathways appear to play a critical role in ATM functions in microglia, responding to various forms of nucleic acid sensors and regulating survival of neurons and other cell types. Overall, the results lead to an updated view of transcriptional stress and DNA damage resulting from ATM loss that results in changes in gene expression as well as neuroinflammation that contribute to the cerebellar neurodegeneration observed in patients.
Journal
|
ATM (ATM serine/threonine kinase)
|
ATM expression
10ms
Integrated bioinformatics approach to unwind key genes and pathways involved in colorectal cancer. (PubMed, J Cancer Res Ther)
The present study proposed five novel therapeutic targets, i.e., ATM, GAPDH, CREB1, VEGFA, and CDH1 genes that might provide new insights into molecular oncogenesis of CRC.
Journal
|
CDH1 (Cadherin 1) • MMP9 (Matrix metallopeptidase 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CREB1 (CAMP Responsive Element Binding Protein 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • IL1B (Interleukin 1, beta)
|
CDH1 expression • ATM expression
10ms
Trial completion date • Trial primary completion date • Metastases
|
ATM expression
|
irinotecan • topotecan • elimusertib (BAY 1895344)
10ms
Boric Acid Affects the Expression of DNA Double-Strand Break Repair Factors in A549 Cells and A549 Cancer Stem Cells: An In Vitro Study. (PubMed, Biol Trace Elem Res)
Moreover, BA up-regulated caspase-3 and E-cadherin expression. Consequently, we can say that BA affects DNA DSB and the apoptotic abilities of LC-SCs.
Preclinical • Journal • Cancer stem • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDH1 (Cadherin 1) • RAD51 (RAD51 Homolog A) • CASP3 (Caspase 3)
|
CDH1 expression • ATM expression
10ms
High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response. (PubMed, J Mol Med (Berl))
Our study has demonstrated that BCAT1 expression can serve as a reliable predictor for AML patients, and PARP inhibitor BMN673 can be used as an effective treatment strategy for patients with high BCAT1 expression...H3K9me3 inhibits ATM expression and blocks cellular DNA damage repair process. Increased sensitivity of BCAT1 high expression AML to PARP inhibitors may be used as an effective treatment strategy in AML patients.
Journal • PARP Biomarker
|
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
ATM expression • BCAT1 expression
|
Talzenna (talazoparib)
11ms
mRNA Expression and Methylation of the RAD51, ATM, ATR, BRCA1, and BRCA2 Genes in Gastric Adenocarcinoma. (PubMed, Biomark Insights)
Our results suggest RAD51, BRCA1, and BRCA2 methylation as a frequent epigenetic mechanism in gastric cancer, support the hypothesis that reduced BRCA1 expression participates in disease progression, and show an association between RAD51 mRNA and perineural invasion and mortality that may be considered unexpected, considering the former immunohistochemical studies. The lack of correlation between immunohistochemistry and mRNA, and even the inverse association, for ATR, can be seen as indicative of action of post-transcriptional or post-translational regulatory mechanisms, to be better investigated.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A)
|
BRCA1 expression • ATM expression • BRCA2 expression
11ms
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer. (PubMed, Cancer Lett)
Finally, we identified a negative correlation between changes in phospho-ATM and PD-L1 levels in TNBC post- and pre-neoadjuvant therapy. This study reveals a novel mechanism by which ATM negatively regulates PD-L1 by downregulating JNK/c-Jun/TNF-α in TNBC, shedding light on the wide application of immune checkpoint blockade therapy for treating multi-line-resistant TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha)
|
PD-L1 expression • ATM expression
12ms
Kaposi's sarcoma herpesvirus exploits the DNA damage response to circularize its genome. (PubMed, Nucleic Acids Res)
Therefore, the DDR mediates KSHV and HSV-1 circularization. This strategy may serve as a general herpesvirus mechanism to initiate latency, and its disruption may provide new opportunities for prevention of herpesvirus disease.
Journal
|
ATM (ATM serine/threonine kinase)
|
ATM expression
12ms
Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia. (PubMed, Anticancer Drugs)
The five AML cell lines demonstrated sensitivity to monotherapy with GSK-368, AZD-1390, or AZD-6738 (EC50 value ranges from 5.461 to 7.349 nM, 5.821 to 10.120 nM, and 7.618 to 10.100 nM, respectively). DNMT1, ATM, and ATR possess potential as therapeutic targets for AML. Both individual targeting and combination targeting of these molecules have been confirmed as promising therapeutic approaches for AML.
Journal
|
DNMT1 (DNA methyltransferase 1)
|
ATM expression
|
ceralasertib (AZD6738) • AZD1390
12ms
Enrollment closed • Metastases
|
ATM expression
|
irinotecan • topotecan • elimusertib (BAY 1895344)
12ms
Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib. (PubMed, Onco Targets Ther)
Further analysis revealed that KU-55933 potentiates Olaparib-induced cell apoptosis by inhibiting ATM phosphorylation. Our study demonstrates that inhibiting ATM could enhance the sensitivity of endometrial cancer to Olaparib, thereby providing a potential alternative treatment for the clinical treatment of endometrial cancer.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
|
ATM underexpression • BRCA mutation • ATM expression
|
Lynparza (olaparib) • KU-55933
almost1year
FAP expression in adipose tissue macrophages promotes obesity and metabolic inflammation. (PubMed, Proc Natl Acad Sci U S A)
Such enhanced energy expenditure is associated with increased levels of norepinephrine (NE) and lipolysis in white adipose tissues, likely due to decreased expression of monoamine oxidase, a NE degradation enzyme, by Fap ATM. Collectively, our study identifies FAP as a previously unrecognized regulator of ATM function contributing to diet-induced obesity and metabolic inflammation and suggests FAP as a potential immunotherapeutic target against metabolic disorders.
Journal • IO biomarker
|
FAP (Fibroblast activation protein, alpha) • CCL8 (C-C Motif Chemokine Ligand 8)
|
FAP expression • ATM expression
almost1year
Trial suspension • Metastases
|
ATM expression
|
irinotecan • topotecan • elimusertib (BAY 1895344)
1year
Boric Acid Alters the Expression of DNA Double Break Repair Genes in MCF-7-Derived Breast Cancer Stem Cells. (PubMed, Biol Trace Elem Res)
Consequently, BA affects some of the DNA DSB repair genes of breast cancer stem cells. Findings from this study could provide new insights into the potential therapeutic application of BA in BC-SC elimination and cancer intervention.
Journal • Cancer stem • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A)
|
BRCA1 expression • ATM expression
1year
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer. (PubMed, Int J Mol Sci)
Thus, this proves that PSPC1 inhibition enhances olaparib sensitivity by targeting DNA damage response in our preclinical model. The combination of olaparib and PSPC1 inhibition merits further clinical investigation to enhance PARP inhibitor efficacy.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CDC25C (Cell Division Cycle 25C) • CDK1 (Cyclin-dependent kinase 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation • ATM expression
|
Lynparza (olaparib)
1year
Lnc-PTCHD4-AS inhibits gastric cancer through MSH2-MSH6 dimerization and ATM-p53-p21 activation. (PubMed, Aging (Albany NY))
Notably, PTCHD4-AS was found to be transcriptionally induced by DNA damage agents and its upregulation led to cell cycle arrest at the G2/M phase, in parallel, it facilitated the cell apoptosis induced by cisplatin (CDDP) in GC. Mechanistically, PTCHD4-AS directly bound to the DNA mismatch repair protein MSH2-MSH6 dimer, and facilitated the binding of dimer to ATM, thereby promoting the expression of phosphorylated ATM, p53 and p21. Here we conclude that the upregulation of PTCHD4-AS inhibits proliferation and increases CDDP sensitivity of GC cells via binding with MSH2-MSH6 dimer, activating the ATM-p53-p21 pathway.
Journal
|
MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
TP53 expression • ATM expression
|
cisplatin
1year
ATM-AMPKα mediated LAG-3 expression suppresses T cell function in prostate cancer. (PubMed, Cell Immunol)
Reconstitution of ATM and inhibition of XBP1 or EGR2 in PCa T cells suppressed LAG3 expression and restored the effector function of CD4 T cells from PCa. Our study revealed the mechanism of LAG3 upregulation in CD4 T lymphocytes of PCa patients and may provide insights for the development of immunotherapeutic strategies for PCa treatment.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • XBP1 (X-box-binding protein 1)
|
LAG3 expression • ATM expression • LAG3 elevation
1year
Enhanced Genomic Stability in Monomorphic Post-Transplant Lymphoproliferative Disorders Is Driven By Distinct Mechanisms Stratified By EBV Status (ASH 2023)
Like HIV associated DLBCL, these results show that PTLD is more genomically stable than IC-DLBCL, and that genomic stability is further enhanced in EBV(+)PTLD which have increased expression of UPS related genes. In contrast, EBV(-)PTLD have increased expression of DNA damage repair genes, including RAD51. In summary, monomorphic DLBCL PTLD tumors have enhanced genomic stability that appears to be mediated by two distinct mechanisms stratified by EBV status.
Post-transplantation
|
MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • EP300 (E1A binding protein p300) • CHEK1 (Checkpoint kinase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCNA2 (Cyclin A2) • PCNA (Proliferating cell nuclear antigen) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • FANCE (FA Complementation Group E) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • FANCB (FA Complementation Group B)
|
RAD51 overexpression • ATM expression
|
nCounter® PanCancer Pathways Panel
1year
Combining Inotuzumab Ozogamicin (IO) with PARP Inhibitors, Olaparib and Talazoparib, Exerts Synergistic Cytotoxicity By Inhibiting the Repair of IO-Induced DNA Strand Breaks in IO-Resistant ALL Cells (ASH 2023)
This would be because the PARP inhibitors were still effective in inhibiting the DNA repair in Reh-IO-R cells where the DNA repair function was not augmented. [Conclusion]The combination of IO with PARP inhibitors synergized the antileukemic effect of IO by inhibiting DNA strand break repair in CD22-positive ALL cell lines and IO-resistant ALL cells, suggesting that these results may contribute to overcoming the IO resistance mechanisms.
BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • CD22 (CD22 Molecule) • CHEK1 (Checkpoint kinase 1) • ANXA5 (Annexin A5)
|
ABCB1 overexpression • CD22 positive • CD22 expression • ATM expression
|
Lynparza (olaparib) • Talzenna (talazoparib) • Besponsa (inotuzumab ozogamicin)
1year
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. (PubMed, Sci Adv)
We show that ATM loss is sufficient to increase sensitivity to DNA-damaging agents including cisplatin and radiation...Last, we show that ATM expression by immunohistochemistry is strongly correlated with response to chemoradiotherapy. Together, these data define a potential role for ATM as a predictive biomarker in bladder cancer.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
ATM expression
|
cisplatin
1year
A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway. (PubMed, Immunol Invest)
The in vivo investigations revealed ATM induced proliferation of CRPC and macrophage recruitment, while the NK cell recruitment was found to suppress ATM expression and CRPC proliferation. In conclusion, it could be demonstrated that inhibiting ATM increased the susceptibility of CRPC to NK cell inhibitors by dampening the CXCL12 and PI3K/AKT-PD-L1 pathways, thereby offering a novel and individualized treatment protocol for treating CRPC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • NKG2D (killer cell lectin like receptor K1)
|
PD-L1 expression • ATM mutation • ATM expression
1year
Invasion-Block and S-MARVEL: A high-content screening and image analysis platform identifies ATM kinase as a modulator of melanoma invasion and metastasis. (PubMed, Proc Natl Acad Sci U S A)
Together, this study established a rapid screening assay coupled with a customized image-analysis pipeline for the identification of antimetastatic drugs. Our study implicates that ATM may serve as a potent therapeutic target for the treatment of melanoma cell spread in patients.
Journal
|
PI3K (Phosphoinositide 3-kinases)
|
ATM expression
1year
IS FLT3 INHIBITION A THERAPEUTIC OPTION FOR TRIPLE NEGATIVE B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS? (SIE 2023)
To evaluate the effect of FLT3 inhibitors in ALL, we treated ex vivo primary leukemic cells of 6 adult ALL patients (FLT3 mut n=4; FLT3 wt n=2) with increasing concentrations of Gilteritinib, Midostaurin, Crenolanib, Sorafenib and Quizartibin for 24, 48 and 72h. AIRC IG 2019 (Project Code: 23810). Figure 1.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KMT2D (Lysine Methyltransferase 2D) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • CREBBP (CREB binding protein) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CSMD1 (CUB And Sushi Multiple Domains 1)
|
FLT3 mutation • FLT3 expression • ATM expression
|
TruSight RNA Pan-Cancer Panel
|
sorafenib • Xospata (gilteritinib) • Rydapt (midostaurin) • crenolanib (ARO-002)
1year
Breast cancer cells are sensitized by piperine to radiotherapy through estrogen receptor-α mediated modulation of a key NHEJ repair protein- DNA-PK. (PubMed, Phytomedicine)
In conclusion, our study for the first time reported that piperine sensitizes breast cancer cells to radiation by accumulating DNA breaks, through altering the expression of DNA-PK Complex, and DDR proteins, via selective estrogen receptor modulation, offering a novel strategy for combating radioresistance.
Journal
|
ER (Estrogen receptor)
|
ER positive • TP53 expression • ER expression • ATM expression
|
cisplatin
1year
Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia. (PubMed, Sci Rep)
The reduction in titers could not be explained by impaired packaging of the viral genomes, but the main differences occurred after transduction. Finally, after transduction of Atm-deficient (ATM-KO) murine fibroblasts with the lentiviral vector expressing Atm, we could show the expression of ATM protein which phosphorylated its downstream substrates (pKap1 and p-p53).
Journal • Gene therapy
|
ATM (ATM serine/threonine kinase)
|
ATM expression
1year
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies. (PubMed, Cancer Res Commun)
Combining C220 or PRT543 with olaparib or chemotherapeutic agents such as cisplatin demonstrates a potent synergistic interaction in breast and ovarian cancer cells in vitro. Furthermore, PRT543 treatment significantly inhibits growth of Olaparib resistant tumors in vivo. These studies reveal a novel mechanism of PRMT5 inhibition and suggest beneficial combinatorial effects with other therapies, particularly in patients with tumors that are resistant to therapies dependent on DNA damage as their mechanism of action.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • PRMT5 (Protein Arginine Methyltransferase 5)
|
ATM expression
|
Lynparza (olaparib) • cisplatin • PRT543
1year
Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer. (PubMed, Prostate)
The data suggest that WC-A compounds exhibit anti-CRPC effects through the inhibition of TOP II activities, leading to mitochondrial stress-involved caspase activation and apoptosis. Moreover, WC-A13, WC-A14, and WC-A15 but not WC-A16 display inhibitory activities of Rad51-mediated DNA repair pathway which may increase apoptotic effect of CRPC cells.
Journal
|
RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
ATM expression
1year
High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL (ASH 2023)
The reported low TMB in CLL does not reflect the true frequency of neoantigens, as it fails to account for BCR neoantigens. These contribute ~80% of the neoantigen pool and are predominantly presented by HLA-II. The majority of BCR neoantigens in M-CLL are within the V region, whereas in U-CLL, BCR neoantigens are largely restricted to the V(D)J recombination site.
Tumor mutational burden • IO biomarker
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • IGH (Immunoglobulin Heavy Locus) • XPO1 (Exportin 1)
|
TP53 mutation • ATM mutation • TMB-L • SF3B1 mutation • IGH mutation • NOTCH1 expression • ATM expression • BCR expression • XPO1 mutation